restructuring
“If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill.”
COO 10-K
Confirmed
Consumer Beverages & Products
15 names are moving together; 100% are participating in the current session.
Co-movement
Observed intraday paths are not available for this group yet.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| KMB | Kimberly-Clark Corporation | Consumer Defensive | -3.0% | Group member |
| UL | Unilever PLC | Consumer Defensive | -1.0% | Group member |
| KVUE | Kenvue Inc. | Consumer Defensive | -2.5% | Group member |
| REYN | Reynolds Consumer Products Inc. | Consumer Cyclical | -0.5% | Group member |
| PG | Procter & Gamble Company (The) | Consumer Defensive | -1.5% | Group member |
| STZ | Constellation Brands, Inc. | Consumer Defensive | -2.3% | Group member |
| COO | The Cooper Companies, Inc. | Healthcare | -4.0% | Most structurally connected |
| HLN | Haleon plc | Healthcare | -1.7% | Group member |
| DEO | Diageo plc | Consumer Defensive | -1.9% | Group member |
| TAP | Molson Coors Beverage Company | Consumer Defensive | -2.5% | Group member |
| CL | Colgate-Palmolive Company | Consumer Defensive | -2.2% | Group member |
| CHD | Church & Dwight Company, Inc. | Consumer Defensive | -1.8% | Group member |
| CCEP | Coca-Cola Europacific Partners | Consumer Defensive | -0.5% | Group member |
| CLX | Clorox Company (The) | Consumer Defensive | -0.4% | Group member |
| SAM | Boston Beer Company, Inc. (The) | Consumer Defensive | -2.1% | Group member |
Why we believe this
Cohort
15 namesParticipation
100% this sessionObserved history
1 daily buildsFiling coverage
11/15 memberspricing affecting revenue
“Sustained, those price increases may lead to declines in volume as competitors may reduce their prices or customers may decide not to pay higher prices or to purchase lower priced alternatives, which could lead to sales declines and loss of market share.”
CHD 10-K
restructuring affecting expense
“2024 % Change CooperVision $ 969.3 35 % $ 910.7 35 % 6 % CooperSurgical 568.4 42 % 534.2 42 % 6 % Corporate 90.1 — 88.8 — 1 % $ 1,627.8 40 % $ 1,533.7 39 % 6 % CooperVision's SGA expenses increased in fiscal 2025 compared to fiscal 2024 primarily due to increased selling activities, severance costs related to workforce optimization initiatives, and long-lived asset write-offs.”
COO 10-K
Cross-asset confirmation is still fragile, so spillover can stall before it becomes durable.
Connected, outside the group
No high-confidence filing-linked non-members are available for this group yet.
History
Historical cohort observations are not available yet.